Signal Breakdown
4 verified publisher articles from recent coverage.
Limited TV coverage this week.
Limited video coverage this week.
GDELT tone + context across verified sources.
What’s Driving Sentiment
Bullish Signals
- Regeneron extended its BARDA procurement with about $270 million of added value for Inmazeb, strengthening U.S. biodefense revenue visibility.
- The company now books its full share of Dupixent profits for the first time, removing a billion-dollar profit drag and potentially boosting EPS.
- Regeneron extended a U.S. supply agreement for its Ebola treatment amid a growing African outbreak, signaling rising government demand.
- Late-breaking Phase 3 C POST data at ESMO showed sustained disease-free survival and emerging overall survival benefits for Libtayo, and analysts see modest.
Risk Factors
- No current risk factors listed.
Evidence
- 2026-10-26Source: TIINGO
Summary: Regeneron reports Q3 on Oct. 30 and now books its full share of Dupixent profits from Sanofi for the first time, removing a billion‑dollar profit drag and potentially boosting EPS versus prior quarters.
Bullish - 2026-10-26Source: TIINGO
Summary: Regeneron extended a U.S. agreement to provide additional supply of its Ebola treatment amid a growing outbreak in Africa, indicating increased government demand and potential revenue and visibility for the company's infectious-disease portfolio.
Bullish - 2026-10-26Source: TIINGO
Summary: Late-breaking Phase 3 C POST data at ESMO 2026 showed sustained disease-free survival and emerging overall survival benefits for Libtayo in high-risk CSCC; analysts suggest REGN could be about 5% undervalued despite a recent 90-day +15.8% and 1-year +38.24% return.
Bullish - 2026-10-26Source: TIINGO
Summary: Regeneron extended its BARDA agreement to provide additional supplies of Inmazeb—the company's first-in-class antibody treatment for Orthoebolavirus zairense—expanding a 2020 procurement deal with about $270 million of added value, reinforcing U.S. biodefense revenue and government partnership, which should be positive for near-term revenue visibility and contract pipeline.
Bullish
Showing 4 of 4 verified news articles
- No current evidence is available for this source.
No current verified Archive TV segments
- No current evidence is available for this source.
No verified video evidence in the current 7-day window
Formula & Methodology
- News
- GDELT discovers coverage; only publisher passages that directly name the company qualify as news evidence.
- TV
- Internet Archive TV captions are retained only with a match-centered quote that directly names the company.
- Video
- Recent Bullish Gator videos tagged to the company; the item summary and publisher label feed the judge.
- Holistic AI judge
- A single Azure OpenAI call reads the news, television, and video evidence together and returns the rating, a 0–100 composite, and a short rationale. Thresholds are enum-only: 65+ Bullish, 35 or lower Bearish, Neutral in between.
Data Source
News evidence comes from the GDELT Global Knowledge Graph (via BigQuery); TV evidence from the Internet Archive TV News Archive; video evidence from recent Bullish Gator video coverage. Azure OpenAI filters per-article relevance and serves as the holistic AI judge that produces the composite rating. Portions use data from The GDELT Project under open data terms. This page is informational analysis, not investment advice. See Financial Disclaimer.